1887
Volume 2021, Issue 3
  • ISSN: 0253-8253
  • EISSN: 2227-0426

Abstract

Introduction: Anemia management in dialysis is challenging. Keeping hemoglobin levels within a tight range is difficult. A new program (anemia nurse manager [ANM]) was started for better anemia management. This study aimed to compare traditional anemia management with the new ANM model regarding the achievement of better hemoglobin targets (range, 10–12 g/dL), avoidance of extreme hemoglobin levels ( < 9 or >13 g/dL), and evaluation of the cost-effectiveness of the new model.

Methods: This retrospective observational study compared traditional anemia management with management involving our new ANM model. Patients on hemodialysis in all ambulatory dialysis clinics in Qatar were included. The study included three phases: phase 1 (observation): June 2015 to August 2015, 460 patients; phase 2 (pilot): September 2015 to May 2016, 211 patients; and phase 3 (expansion in two phases): June 2016 to February 2017 and October 2017 to June 2018, 610 patients. Hemoglobin, iron saturation, and ferritin were evaluated according to the protocol.

Results: In this study, 55% of the patients achieved the target hemoglobin in phase 1 compared with 75% in phase 2 ( = 0.0007). The hemoglobin level within the target range was sustained at 72% ± 5% of patients in phase 3. The achievement rate of the target hemoglobin level increased from 56% (May 2015) to 72% (July 2018) ( < 0.001). The proportion of patients with extreme hemoglobin declined from 10.7% in phase 1 to 6.4% in phase 2 and sustained at 8% afterward. Reducing the doses of erythropoietin stimulating agents, owing to the use of the ANM model, saved costs by approximately 11%.

Conclusions: The ANM model was able to achieve and maintain hemoglobin levels within the target range and decrease extreme hemoglobin levels. These outcomes improved patient care by avoiding high hemoglobin (increase thrombosis, cancer recurrence, stroke, and death) and low hemoglobin (weakness, poor quality of life, and need for transfusion) levels. The ANM model was cost effective even after including the salaries of nurses. This model can be considered in other aspects of patient care in dialysis.

Loading

Article metrics loading...

/content/journals/10.5339/qmj.2021.46
2021-10-21
2021-12-02
Loading full text...

Full text loading...

/deliver/fulltext/qmj/2021/3/qmj.2021.46.html?itemId=/content/journals/10.5339/qmj.2021.46&mimeType=html&fmt=ahah

References

  1. Hsu C, McCulloch C, Curhan G. Epidemiology of anemia associated with chronic renal insufficiency among adults in the United States: results from the Third National Health and Nutrition Examination Survey. J Am Soc Nephrol. 2002; 1312:(2):504–510. https://doi.org/10.1681/asn.v132504 .
    [Google Scholar]
  2. Eschbach JW, Mladenovic J, Garcia JF, Wahl PW, Adamson JW. The anemia of chronic renal failure in sheep. Response to erythropoietin-rich plasma in vivo. J Clin Invest. 1984; 74:(2):434–441. doi: 10.1172/JCI111439 .
    [Google Scholar]
  3. Fishbane S, Spinowitz B. Update on anemia in ESRD and earlier stages of CKD: core curriculum. Am J Kidney Dis. 2018; 71:(3):423–435. doi: 10.1053/j.ajkd.2017.09.026 .
    [Google Scholar]
  4. Cappellini MD, Motta I. Anemia in clinical practice—definition and classification: does hemoglobin change with aging? Semin Hematol. October 2015; 52:(4):261–269. https://doi.org/10.1053/j.seminhematol.2015.07.006 .
    [Google Scholar]
  5. Canadian Erythropoietin Study Group. Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving hemodialysis. Canadian Erythropoietin Study Group. BMJ. 1990 Mar; 300:(6724):573–578. doi: 10.1136/bmj.300.6724.573 .
    [Google Scholar]
  6. Delano BG. Improvements in quality of life following treatment with r-HuEPO in anemic hemodialysis patients. Am J Kidney Dis. 1989; 14:(2)(suppl 1):14–18.
    [Google Scholar]
  7. Collister D, Komenda P, Hiebert B, Gunasekara R, Xu Y, Eng F, et al. The effect of erythropoietin-stimulating agents on health-related quality of life in anemia of chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med. 2016 Apr 5; 164:(7):472–478. doi: 10.7326/M15-1839 .
    [Google Scholar]
  8. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, et al. CHOIR Investigators. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006; 355:(20):2085–2098. https://doi.org/10.1056/nejmoa065485 .
    [Google Scholar]
  9. Pfeffer MA, Burdmann EA, Chen CY, Cooper M, de Zeeuw D, Eckardt K, et al. TREAT Investigators. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009; 361:(21):2019–2032. doi: 10.1056/NEJMoa0907845 .
    [Google Scholar]
  10. Drüeke TB, Locatelli F, Clyne N, Eckardt K, Macdougall IC, Tsakiris D, et al. CREATE Investigators. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006; 355:(20):2071–2084. https://doi.org/10.1056/nejmoa062276 .
    [Google Scholar]
  11. Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med. 1998; 339:(9):584–590. https://doi.org/10.1056/nejm199808273390903 .
    [Google Scholar]
  12. KDOQI KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target. Am J Kidney Dis. 2007 Sep; 50:(3):471–530. doi: 10.1053/j.ajkd.2007.06.008 .
    [Google Scholar]
  13. Kidney Disease: Improving Global Outcomes (KDIGO) Work Group Chapter 1: diagnosis and evaluation of anemia in CKD. Kidney Int Suppl (2011) 2012 Aug; 2:(4):288–291. doi: 10.1038/kisup.2012.33 .
    [Google Scholar]
  14. Mikhail A, Brown C, Williams JA, Mathrani V, Shrivastava R, Evans J, et al. Renal association clinical practice guideline on Anemia of Chronic Kidney Disease. BMC Nephrol. 2017; 18:(1):345. doi: 10.1186/s12882-017-0688-1 .
    [Google Scholar]
  15. Ghonimi TA, Hamad A, Iqbal Z, Yasin F, Ali F, Ismail S, et al. Mortality of dialysis patients in Qatar: a retrospective epidemiologic study. Qatar Med J. 2021 Feb 17; 2021:(1):02 https://doi.org/10.5339/qmj.2021.2 .
    [Google Scholar]
  16. He J, Shlipak M, Anderson A, Roy J, Feldman H, Kallem, R, et al. Risk factors for heart failure in patients with chronic kidney disease: the CRIC (Chronic Renal Insufficiency Cohort) study. J Am Heart Asso. 2017; 6:(5), 1–9. https://doi.org/10.1161/jaha.116.005336 .
    [Google Scholar]
  17. Drüeke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006; 355:(20), 2071-2084. https://doi.org/10.1056/NEJMoa062276 .
    [Google Scholar]
  18. Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. New England Journal of Medicine. 2009; 361:(21), 2019–2032. https://doi.org/10.1056/NEJMoa0907845 .
    [Google Scholar]
  19. Singh A K, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M., et al. Correction of anemia with epoetin alfa in chronic kidney disease. New Eng J Med. 2006; 355:(20),2085–2098. https://doi.org/10.1056/NEJMoa065485 .
    [Google Scholar]
  20. Mikhail A, Brown C, Williams JA, Mathrani V, Shrivastava R, Evans J, et al. The Renal Association. Clinical practice guideline Anemia of chronic kidney disease. Update Feb 2020 Retrieved from https://renal.org/wp-conte nt/uploads/2017/06/Anemia-of-chronic-kidney-disease5d84a231 18156165944 3ff000014d4d8.pdf .
    [Google Scholar]
  21. Gardiner R, Roshan D, Brennan A, Connolly D, Murray S, Reddan D. Trends in the treatment of chronic kidney disease-associated anemia in a cohort of hemodialysis patients: the Irish experience. Ir J Med Sci. 2019 Feb; 188:(1), 223–230. https://doi.org/10.1007/s11845-018-1823-0 .
    [Google Scholar]
  22. Gerrish, M. Nonmedical prescribing and anaemia management on the unit. J Renal Nurs. 2014; 634:(1),10–17. https://doi.org/10.12968/jorn.2014.6.1.10 .
    [Google Scholar]
  23. Yong K, Kairaitis L. Effects of proactive iron and erythropoiesis- stimulating agent protocol implementation on achieving clinical guideline targets for Anemia in a satellite hemodialysis patient cohort. Nephrology (Carlton). 2009; 15:(3), 288–293. https://doi.org/10.1111/j.1440-1797.01184.x .
    [Google Scholar]
  24. George S, McCann M. A nurse prescriber-led protocol for Anemia management in established hemodialysis patients: a retrospective study. J Clin Nurs. 2020; 295:(13–14)6:2535-2543.
    [Google Scholar]
  25. Drennan, J., Naughton, C., Allen, D., Hyde, A., Felle, P, O'Boyle, K, et al. Independent evaluation of the nurse and midwife prescribing initiative. Dublin, Ireland: University College Dublin. 2009.
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journals/10.5339/qmj.2021.46
Loading
/content/journals/10.5339/qmj.2021.46
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error